Last reviewed · How we verify
GFH276
At a glance
| Generic name | GFH276 |
|---|---|
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GFH276 CI brief — competitive landscape report
- GFH276 updates RSS · CI watch RSS
- Genfleet Therapeutics (Shanghai) Inc. portfolio CI